A cyclometalated iridium(III) complex that inhibits the migration and invasion of MDA-MB-231 cells |
| |
| Affiliation: | 1. Guangdong Provincial Key Laboratory of Biotechnology Candidate Drug Research, Guangdong Pharmaceutical University, Guangzhou 510006, PR China;2. Huaihua Medical College, Huaihua 418000, PR China;3. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, PR China;1. Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, PR China;2. School of Life Sciences, Tsinghua University, Beijing 100010, PR China;1. FOCAS Research Institute/School of Chemical and Pharmaceutical Sciences, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland;2. School of Physics, Clinical and Optometric Science, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland;3. School of Chemistry, Trinity College, Dublin 2, Ireland;4. School of Food Science and Environmental Health, Dublin Institute of Technology, Cathal Brugha St, Dublin 1, Ireland |
| |
| Abstract: | A cyclometalated iridium(III) complex, [Ir(ppy)2(PCN)]Cl (Ir1, ppy = 2-phenylpyridine, PCN = 2-(4-cyanophenyl)imidazo[4,5-f] [1,10] phenanthroline), was synthesized and characterized in the present study. Ir1 inhibited the proliferation, migration and invasion of MDA-MB-231 human breast cancer cells in a dose-dependent manner. Moreover, Ir1 down-regulated the phosphorylation of AKT/ERK signal pathways. According to confocal fluorescence microscopy analysis, Ir1 was primarily localized within the mitochondria and induced apoptosis through an intrinsic mitochondria-mediated apoptotic pathway. Thus, Ir1 exhibited both antimetastatic and antineoplastic properties, indicating that Ir1 may be a viable drug candidate in antimetastasis and anticancer therapies. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
